Appili to Spend US$1M on Covid Drug Trials
Halifax drugmaker Appili Therapeutics has raised US$1 million from FUJIFILM Toyama Chemical Co. to pay for ongoing clinical trials of the Japanese pharma giant’s favipiravir antiviral medication, which the two companies hope will prove useful in treating COVID-19.
Favipiravir, sold under the names Avigan and Reeqonus, was approved for use in treating influenza pandemics by the Japanese